VIENNA — A 6-month interim analysis of Eylea HD demonstrated stable visual acuity, decreased central retinal thickness, increased retinal drying and no new safety signals.
SPECTRUM is an ongoing, global, phase 4 prospective observational study evaluating the real-world effectiveness and safety of Eylea HD (aflibercept 8 mg, Regeneron/Bayer) in patients with age-related macular degeneration or diabetic macular edema. At the Euretina congress, Marion R. Munk, MD, PhD, presented new outcomes for the neovascular AMD subgroup.
“The pretreated neovascular AMD group included 1,100 patients who had